Scienture Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.8M
- Price
- $4.13
- % Change (Daily % change from the live per-ticker quote feed.)
- +9.84%
- Volume
- 106.3K
About
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Quick stats
Shares outstanding1.6M
Computed float1.3M
Float / shares76.9%
Cash runway (months)4.8
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001382574
Websitehttps://scienture.com
AI Summary
AI-generated1/14
minorbullishoperations update
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Scienture Holdings announced that Arbli, its FDA-approved liquid losartan oral suspension, has been added to the formularies of three leading U.S. pediatric academic medical centers and hospitals.
Arbli targets an approximately $219 million U.S. losartan market with roughly 72 million prescriptions annually, and the company says wholesale orders are increasing sequentially.
The formulary wins support broader institutional adoption, but no revenue contribution or financial impact was quantified in the release.
Red flags
- no quantified revenue from Arbli to date
- forward-looking statement risk factors cite going concern, potential dilution, and Nasdaq listing maintenance